Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

In vivo safety assessment of METTL3 inhibitors STM2457 in neuroblastoma therapy

ABSTRACT: Neuroblastoma (NB) is one of the most common malignant tumors in children, characterized by high heterogeneity and poor prognosis, posing notable therapeutic challenges. The present study investigated the therapeutic potential and safety profile of two N6-adenosine-methyltransferase 70 kDa subunit (METTL3) inhibitors, UZH1a and STM2457, in NB. A toxicity test of zebrafish showed that the maximum tolerated concentration of UZH1a and STM2457 was 20 μg/ml, and there were some toxic reactions including delayed yolk sac absorption but without notable mortality. Furthermore, through a series of in vitro and in vivo experiments, both UZH1a and STM2457 markedly inhibited SK-N-SH cells viability, migration and invasion, while potently promoting apoptosis, and effectively inhibiting the growth and migration of zebrafish xenograft tumors. Mechanistically, molecular analysis revealed that UZH1a and STM2457 downregulated the gene expression levels of pro-tumorigenic factors (basic helix-loop-helix family member e41, SREBF chaperone, IL-6, and IL-1β) and upregulated the expression of antitumor cytokine (TNF-α). Transcriptomic sequencing results further indicated that the neuroactive ligand-receptor interaction is a key pathway through which STM2457 affected NB development. In conclusion, UZH1a and STM2457 exhibited potent anti-NB activity both in vitro and in vivo by inhibiting viability, migration, invasion, and promoting apoptosis. These findings provide a notable theoretical basis for potential use of METTL3 inhibitors as therapeutic agents against NB.

ORGANISM(S): Homo sapiens

PROVIDER: GSE306644 | GEO | 2026/06/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-seq of human breast cancer cell line MDA-MB-231 treated with STM2457 against untreated controls

Project description:Here, we aim to investigate if catalytic inhibition of the m6A methyltransferase METTL3 by the small-molecule STM2457 may be a viable treatment option for TNBC.

2023-12-18 | E-MTAB-13184 | biostudies-arrayexpress

AN465: A Novel Therapeutic Targeting METTL3 Inhibition in Hand, Foot, and Mouth Disease

Project description:Abstract: Hand, foot, and mouth disease (HFMD) is a widespread viral infection predominantly affecting young children, for which specific therapies remain elusive despite extensive research efforts. N6-methyladenosine (m6A) modifications, prevalent in eukaryotic mRNA and long non-coding RNAs, are also found in various viral RNAs. A nuclear methyltransferase complex, including METTL3 as the catalytic subunit, catalyzes these m6A modifications co-transcriptionally, functioning as m6A 'writers'. Notably, enterovirus 71 (EV71) RNA undergoes m6A modification during infection, mediated by METTL3, influencing virus replication. We hypothesized that inhibiting METTL3 could directly suppress EV71 replication through m6A modifications. Despite the renown of STM2457 as a METTL3 inhibitor, our preliminary experiments indicated its ineffectiveness against EV71. Leveraging a compound library tenfold larger than that in STM2457's discovery, we identified AN465 as a potent METTL3 inhibitor. Through rigorous experiments and analyses, we demonstrate that AN465 surpasses STM2457 in inhibiting EV71 replication by effectively targeting METTL3. Our findings propose AN465 as a promising therapeutic candidate for combating HFMD by curbing EV71 replication.

2026-03-21 | GSE291299 | GEO

Lymphatic-specific Methyltransferase3-mediated m6A modification drives vascular patterning through prostaglandin metabolism reprogramming

Project description:Lymphangiogenesis plays a pivotal role in the pathogenesis of various vascular disorders, including ocular vascular diseases and cancers. Deregulation of N6-methyladenosine (m6A) modification has been identified as a key contributor to human diseases. However, the specific involvement of m6A modification in lymphatic remodeling remains poorly understood. In this study, we demonstrate that inflammatory stimulation and corneal sutures induce elevated levels of METTL3-mediated m6A modification. METTL3 knockdown inhibits lymphatic endothelial viability, proliferation, migration, and tube formation in vitro. METTL3 knockdown attenuates corneal sutures-induced lymphangiogenesis and intratumoral lymphangiogenesis initiated by subcutaneous grafts, consequently restraining corneal neovascularization, tumor growth, and tumor neovascularization in vivo. Mechanistically, METTL3 knockdown upregulates prostaglandin-endoperoxide synthase 2 (PTGS2) expression through an m6A-YTHDF2-dependent pathway, enhancing the synthesis of cyclopentenone prostaglandins (CyPGs). Aberrant CyPG production in lymphatic endothelial cells impairs mitochondrial oxidative phosphorylation, contributing to pathological lymphangiogenesis. Moreover, selective inhibition of METTL3 with STM2457 reduces m6A levels in lymphatic endothelial cells, effectively suppressing pathological lymphangiogenesis. This study provides compelling evidence that lymphatic-specific METTL3 plays a critical role in vascular patterning through prostaglandin metabolism reprogramming. Thus, METTL3 emerges as a promising target for treating pathological lymphangiogenesis.

2024-10-15 | GSE273930 | GEO

Small-molecule Inhibition of METTL3 Suppresses Tumor Growth and Promotes Neuroblastoma Differentiation [RNA-Seq STM]

Project description:The N6-methyladenosine (m6A) RNA modification is an important regulator of gene expression. m6A is deposited by a methyltransferase complex that includes methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14). High levels of METTL3 and METTL14 drive the growth of many types of adult cancer, and METTL3/METTL14 inhibitors are emerging as new anticancer agents. However, little is known about the m6A epitranscriptome or the role of the METTL3/METTL14 complex in neuroblastoma, a common pediatric cancer. Here, we show that METTL3 knockdown or pharmacologic inhibition with the small molecule STM2457 leads to reduced neuroblastoma cell proliferation and increased differentiation. These changes in neuroblastoma phenotype were associated with decreased m6A deposition on transcripts involved in nervous system development and neuronal differentiation and increased stability and expression of target mRNAs. In preclinical studies, STM2457 treatment suppressed the growth of neuroblastoma tumors in vivo. Together, these results support the potential of METTL3/METTL14 complex inhibition as therapeutic strategy against neuroblastoma.

2024-04-10 | GSE262731 | GEO

Small-molecule Inhibition of METTL3 Suppresses Tumor Growth and Promotes Neuroblastoma Differentiation [meRIP-Seq]

2024-04-10 | GSE240582 | GEO

Small-molecule Inhibition of METTL3 Suppresses Tumor Growth and Promotes Neuroblastoma Differentiation [RNA-Seq Decay]

2024-04-10 | GSE240581 | GEO

Small-molecule Inhibition of METTL3 Suppresses Tumor Growth and Promotes Neuroblastoma Differentiation [RNA-seq siMETTL3]

2024-04-10 | GSE263118 | GEO

CHD5 inhibits metastasis of neuroblastoma

Project description:CHD5, a tumor suppressor at 1p36, is frequently lost or silenced in poor prognosis neuroblastoma (NB) and many adult cancers. The role of CHD5 in metastasis is unknown. We confirm that low expression of CHD5 is associated with stage 4 NB. Forced expression of CHD5 in NB cell lines with 1p loss inhibited key aspects of the metastatic cascade in vitro: anchorage-independent growth, migration and invasion. In vivo, formation of bone marrow and liver metastases developing from intravenously injected NB cells was delayed and decreased by forced CHD5 expression. Genome-wide mRNA sequencing revealed reduction of genes and gene sets associated with metastasis when CHD5 was overexpressed. Known metastasis-suppressing genes preferentially up-regulated in CHD5-overexpressing NB cells included PLCL1. In patient NB, low expression of PLCL1 was associated with metastatic disease and poor survival. Knock-down of PLCL1 and of p53 in IMR5 NB cells overexpressing CHD5 reversed CHD5-induced inhibition of invasion and migration in vitro. In summary, CHD5 is a metastasis suppressor in NB.

2021-09-11 | GSE183824 | GEO

The METTL3 RNA methyltransferase regulates gene expression in castrate resistant LNCaP:C42 prostate cancer cells

Project description:RNA sequencing was used to determine the effect of the STM2457 METTL3 inhibitor on prostate cancer cell gene expression.

2022-11-02 | GSE195632 | GEO

The METTL3 RNA methyltransferase regulates gene expression in castrate resistant 22Rv1 prostate cancer cells

Project description:RNA sequencing was used to determine the effect of the STM2457 METTL3 inhibitor on prostate cancer cell gene expression.

2022-11-02 | GSE195624 | GEO